rare diseases

Swiss drugmaker Roche wins U.S. & British approval for its $4.3B acquisition of Spark Therapeutics

By admin1 on December 17, 2019 • ( 0 )

Swiss drugmaker Roche has won approval from U.S. antitrust authorities for its $4.3 billion bid to acquire gene therapy specialist Spark Therapeutics. The development clears the way for Roche’s strategic push to position itself in the treatment of rare diseases,… Read More ›

Japan’s Takeda Pharma set to acquire Shire for $61.5 billion

By admin1 on May 8, 2018 • ( 0 )

The deal, one of the largest in the pharma industry, will place Takeda Pharma into the top ranks of global drugmakers. On Tuesday, in a strategic move Japan’s Takeda Pharma stated it has agreed to acquire London-listed Shire for $61.50… Read More ›